GO-Dx Corporation Ltd (Aust) Celebrates Listing on NSX
[July 16, 2024] – GO-Dx Corporation Ltd (Aust) (Ticker: GD8), a forefront innovator in diagnostic and health profiling technologies, today proudly announces the commencement of trading of its shares on the National Stock Exchange (NSX).
Founded with a mission to revolutionize diagnostic and precision medicine solutions, GO-Dx has swiftly emerged as a pivotal player in the healthcare technology sector. The NSX listing marks a significant milestone in the company’s trajectory, enhancing visibility and expanding accessibility to a broader investor community.
Dr Lim Kah Meng, CEO of GO-Dx Corporation (Aust) Ltd, commented, “We are thrilled to embark on this new phase of growth and development as a publicly listed entity on the NSX. This milestone will empower us to fortify our market position, accelerate innovation, and drive sustained value creation for our shareholders.”
The listing underscores GO-Dx’s unwavering commitment to transparency, accountability, and shareholder value. The company remains steadfast in advancing its mission to deliver state-of-the-art diagnostic and precision medicine solutions that elevate patient outcomes on a global scale.
About GO-Dx Corporation Ltd (Aust)
GO-Dx Corporation (Aust) Ltd is a pioneering healthcare technology company specializing in advanced diagnostic and precision medicine solutions. With a focus on innovation and customer-centricity, GO-Dx is dedicated to enhancing diagnostic and health profiling accuracy and efficiency across diverse healthcare settings.
For detailed listing information, please visit GO-Dx Corporation (Aust) Ltd NSX Listing.